271 related articles for article (PubMed ID: 2177891)
1. [Neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) as serum markers in the diagnosis of bronchial carcinoma].
Lorenz J; Gillmann-Blum D; Jensen M; Kreienberg R
Pneumologie; 1990 Nov; 44(11):1259-63. PubMed ID: 2177891
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
3. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
4. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
6. [Clinical investigation of neuron-specific enolase, squamous cell carcinoma-related antigen and carcinoembryonic antigen in carcinoma of the lung].
Tashiro T; Nagai H; Yamasaki H; Kuroda Y; Goto Y; Goto J; Nasu M
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2383-8. PubMed ID: 3015044
[TBL] [Abstract][Full Text] [Related]
7. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
8. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
Kohno N; Hirasawa Y; Kondo K; Fujioka S; Fujino S; Abe M; Yokoyama A; Hiwada K; Watanabe K; Nishimura J
Cancer Detect Prev; 1997; 21(2):124-8. PubMed ID: 9101072
[TBL] [Abstract][Full Text] [Related]
10. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
11. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
12. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
[TBL] [Abstract][Full Text] [Related]
14. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
15. Cut-off levels of NSE to differentiate SCLC from NSCLC.
Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
[TBL] [Abstract][Full Text] [Related]
16. [Neuron-specific enolase as a tumor marker in small cell bronchial carcinoma].
Gasser RW; Herold M; Müller-Holzner E; Müller LC; Salzer GM; Huber H
Dtsch Med Wochenschr; 1988 Nov; 113(44):1708-13. PubMed ID: 2846253
[TBL] [Abstract][Full Text] [Related]
17. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
18. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
[TBL] [Abstract][Full Text] [Related]
19. [Value of neuron specific enolase levels and squamous cell carcinoma antigen in bronchial lavage fluid in patients with lung cancer].
Załteska J; Pirozyński M; Kwiek S; Sakowicz A; Rowińska-Zakrzewska E
Pneumonol Alergol Pol; 1996; 64(1-2):11-8. PubMed ID: 8630459
[TBL] [Abstract][Full Text] [Related]
20. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]